Eikon Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Eikon Therapeutics, Inc. Common Stock (EIKN) has an Asset Resilience Ratio of 41.26% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see EIKN total assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Eikon Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read total liabilities of Eikon Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Eikon Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See defensive interval ratio of Eikon Therapeutics, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $351.03 Million | 41.26% |
| Total Liquid Assets | $351.03 Million | 41.26% |
Asset Resilience Insights
- Very High Liquidity: Eikon Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 41.26% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eikon Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Eikon Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.81% |
Annual Asset Resilience Ratio for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Eikon Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.85% | $231.07 Million | $594.73 Million | +20.34pp |
| 2024-12-31 | 18.51% | $90.93 Million | $491.24 Million | -41.91pp |
| 2023-12-31 | 60.42% | $317.63 Million | $525.71 Million | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more